Verastem, Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

VSTM$8.73+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)


· · Year Ended December 31, ·
· 2024 · 2023 · 2022
Revenue:
Sale of COPIKTRA license and related assets	$10,000	$—	$2,596
Total revenue	10,000	—	2,596
Operating expenses:
Research and development	81,334	61,356	50,558
Selling, general and administrative	43,622	30,728	24,975
Total operating expenses	124,956	92,084	75,533
Loss from operations	(114,956)	(92,084)	(72,937)
Other income (expense)	(123)	(109)	47
Interest income	4,149	6,214	1,215
Interest expense	(4,562)	(4,139)	(2,137)
Change in fair value of preferred stock tranche liability	4,189	2,751	—
Change in fair value of warrant liability	(19,149)	—	—
Net loss before taxes	(130,452)	(87,367)	(73,812)
Income tax expense	(185)	—	—
Net loss	(130,637)	(87,367)	(73,812)
Net loss per share—basic and diluted	(3.66)	(3.96)	(4.57)

Weighted average common shares outstanding used in computing net loss per share—basic and diluted	35,713	22,054	16,138

Net loss	$(130,637)	$(87,367)	$(73,812)
Unrealized gain (loss) on available-for-sale securities	(13)	13	(34)
Comprehensive loss	$(130,650)	$(87,354)	$(73,846)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.